{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-264196","form_type":"8-K","ticker":"SGHT","cik":"0001531177","company_name":"Sight Sciences, Inc.","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.400697+00:00","generated_at":"2026-06-09T08:30:57.725570+00:00","sec_items":["7.01","8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sight Sciences faces Medicare coverage threat for OMNI system; 63% of Surgical Glaucoma revenue at risk","bullets":["WPS LCD classifies OMNI procedure as investigational, effective Dec 24, 2023; WPS states ~8% of 2022 Surgical Glaucoma revenue.","Four other MACs proposed similar LCDs; combined five MACs ~63% of 2022 Surgical Glaucoma revenue.","Company evaluating FY 2023 guidance due to uncertain coverage; update on Nov 7 earnings call.","Company disputes LCD, submitted 36-month GEMINI study for publication; will pursue all remediation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-264196","json":"https://secwatch.observer/filing/0001193125-23-264196.json","markdown":"https://secwatch.observer/filing/0001193125-23-264196.md","text":"https://secwatch.observer/filing/0001193125-23-264196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531177/000119312523264196/0001193125-23-264196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531177/000119312523264196/d545751d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T08:30:57.725570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}